NCT07611240 Sevoflurane vs Propofol Anesthesia in Obese Patients Undergoing Lumbar Surgery
| NCT ID | NCT07611240 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ataturk University |
| Condition | Obesity & Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-06-15 |
| Primary Completion | 2026-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-06-15 with a primary completion date of 2026-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, single-center, single-masked clinical trial aims to compare the immunomodulatory effects of sevoflurane-based inhalational anesthesia and propofol-based total intravenous anesthesia in obese patients undergoing elective lumbar instrumentation surgery. Seventy patients will be randomized into two groups: a propofol group and a sevoflurane group. Blood samples will be collected preoperatively, at postoperative 6 hours, and at postoperative 24 hours. Pentraxin-3 and serum amyloid A levels will be evaluated as primary inflammatory biomarkers together with IL-6, TNF-α, CRP, glucose, and complete blood count parameters.
Eligibility Criteria
Inclusion Criteria: * Patients aged between 18 and 65 years * Patients scheduled for elective lumbar instrumentation surgery * Body mass index between 30 and 34.9 kg/m² * Patients who provided written informed consent Exclusion Criteria: * Known allergy to inhalational or intravenous anesthetic agents * Acute or chronic infectious disease * Autoimmune disease or immunodeficiency * Surgery within the last 3 months * Chronic anti-inflammatory or immunomodulatory drug use * Morbid obesity, defined as BMI \>35 kg/m² * History of malignancy or active cancer treatment * Renal failure, defined as GFR \<60 mL/min * Liver failure, defined as AST or ALT greater than 2 times the upper limit of normal * Diabetes mellitus, metabolic syndrome, or insulin resistance * Pregnancy or lactation * Neurological disease, including epilepsy, multiple sclerosis, or Parkinson's disease * Alcohol or substance abuse * Inability to comply with the study protocol or provide informed consent * Known allergy to study drugs (propofol, sevoflurane, remifentanil) * Emergency surgery
Contact & Investigator
Ayşe Ceren Hilal Güven, assistant doctor
STUDY CHAIR
Ataturk University Department of Anesthesiology and Reanimation
Frequently Asked Questions
Who can join the NCT07611240 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07611240 currently recruiting?
Yes, NCT07611240 is actively recruiting participants. Contact the research team at mehmetakifyilmaz025@gmail.com for enrollment information.
Where is the NCT07611240 trial being conducted?
This trial is being conducted at Erzurum, Turkey (Türkiye).
Who is sponsoring the NCT07611240 clinical trial?
NCT07611240 is sponsored by Ataturk University. The principal investigator is Ayşe Ceren Hilal Güven, assistant doctor at Ataturk University Department of Anesthesiology and Reanimation. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.